The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of patients with advanced NF1-mutant melanoma treated with MEK inhibitors.
 
Lin Wang
No Relationships to Disclose
 
Kevin B. Kim
Stock and Other Ownership Interests - Arvinas; Cryoport
Honoraria - Bristol Myers Squibb Foundation; Genentech; Merck; Novartis; Regeneron; Sanofi; Seagen
Consulting or Advisory Role - AVEO; Bristol Myers Squibb Foundation; Genentech; Merck; Novartis; Regeneron; Sanofi; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Regeneron (Inst)
 
Mohammed Kashani-Sabet
Stock and Other Ownership Interests - DNARx; Melanoma Diagnostics, Inc.
Honoraria - Medscape
Consulting or Advisory Role - Bristol-Myers Squibb
 
Prasad R. Dighe
No Relationships to Disclose
 
Ali Aboosaiedi
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Foundation Medicine